company background image

Merrimack Pharmaceuticals NasdaqGM:MACK Stock Report

Last Price


Market Cap







19 May, 2022


Company Financials
MACK fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

MACK Stock Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company.

Merrimack Pharmaceuticals Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Merrimack Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.25
52 Week HighUS$7.41
52 Week LowUS$3.66
1 Month Change-12.06%
3 Month Change-15.32%
1 Year Change-18.61%
3 Year Change-16.00%
5 Year Change-84.56%
Change since IPO-91.31%

Recent News & Updates

Mar 19
Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although made...

May 19
We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

MACKUS BiotechsUS Market

Return vs Industry: MACK exceeded the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: MACK underperformed the US Market which returned -11.5% over the past year.

Price Volatility

Is MACK's price volatile compared to industry and market?
MACK volatility
MACK Average Weekly Movement8.1%
Biotechs Industry Average Movement12.4%
Market Average Movement8.0%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: MACK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MACK's weekly volatility (8%) has been stable over the past year.

About the Company

1993n/aGary Crocker

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals Fundamentals Summary

How do Merrimack Pharmaceuticals's earnings and revenue compare to its market cap?
MACK fundamental statistics
Market CapUS$67.72m
Earnings (TTM)-US$1.89m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MACK income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.89m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did MACK perform over the long term?

See historical performance and comparison


Is Merrimack Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: MACK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MACK is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MACK's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MACK is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Merrimack Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Merrimack Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MACK is currently unprofitable.

Growing Profit Margin: MACK is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MACK is unprofitable, but has reduced losses over the past 5 years at a rate of 61.9% per year.

Accelerating Growth: Unable to compare MACK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MACK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: MACK has a negative Return on Equity (-13.44%), as it is currently unprofitable.

Financial Health

How is Merrimack Pharmaceuticals's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MACK's short term assets ($14.6M) exceed its short term liabilities ($564.0K).

Long Term Liabilities: MACK has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: MACK is debt free.

Reducing Debt: MACK currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MACK has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MACK is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 46.9% per year.


What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MACK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MACK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MACK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MACK's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MACK has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Gary Crocker (69 yo)





Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe...

CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD105.44K) is below average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MACK's management team is seasoned and experienced (5.4 years average tenure).

Board Members

Experienced Board: MACK's board of directors are considered experienced (4.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: MACK insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Merrimack Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Merrimack Pharmaceuticals, Inc.
  • Ticker: MACK
  • Exchange: NasdaqGM
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$67.722m
  • Shares outstanding: 13.41m
  • Website:

Number of Employees


  • Merrimack Pharmaceuticals, Inc.
  • One Broadway
  • 14th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.